These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25319391)

  • 21. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
    Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
    BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R/JAK1/STAT3 signaling by sponging miR-647.
    Wang R; Ye H; Yang B; Ao M; Yu X; Wu Y; Xi M; Hou M
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110879. PubMed ID: 37713785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
    Becker MA; Farzan T; Harrington SC; Krempski JW; Weroha SJ; Hou X; Kalli KR; Wong TW; Haluska P
    Mol Cancer Ther; 2013 Dec; 12(12):2909-16. PubMed ID: 24130056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
    Campia I; Buondonno I; Castella B; Rolando B; Kopecka J; Gazzano E; Ghigo D; Riganti C
    PLoS One; 2015; 10(5):e0126159. PubMed ID: 25955018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
    Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
    Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
    Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
    Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
    Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
    Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
    Song L; Rawal B; Nemeth JA; Haura EB
    Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
    Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
    Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.
    Jia Y; Shi H; Cao Y; Feng W; Li M; Li X
    Life Sci; 2019 Sep; 233():116715. PubMed ID: 31376371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
    Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
    Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
    Zou M; Zhang X; Xu C
    Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
    Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
    Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
    Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
    Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.